243 filings
Page 5 of 13
8-K
1wnl9tp7sp
23 Sep 22
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
4:53pm
8-K
azxyryxbshqu
20 Sep 22
Regulation FD Disclosure
1:13pm
S-8 POS
63hwij
20 Sep 22
Registration of securities for employees (post-effective amendment)
9:18am
S-8 POS
vjhl3kjp
20 Sep 22
Registration of securities for employees (post-effective amendment)
9:16am
POS AM
jgsa6j85f1l
20 Sep 22
Prospectus update (post-effective amendment)
9:15am
POS AM
fncc54xa4 mcx24dp
20 Sep 22
Prospectus update (post-effective amendment)
9:14am
POS AM
tzlr98o
20 Sep 22
Prospectus update (post-effective amendment)
9:14am
POS AM
wzf6 qv3yy67dk4
20 Sep 22
Prospectus update (post-effective amendment)
9:13am
POS AM
ol62exz31le
20 Sep 22
Prospectus update (post-effective amendment)
9:10am
8-K
riklif2
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
8-K
0mug ggv89sfnozjur
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm
8-K
d3n0zd05e7kwtrqy3lry
26 Aug 22
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
5:30pm
8-K
j80oasd0w73 mjg34
10 Aug 22
InMed Announces Changes to its Board of Directors
8:12pm
8-K
dzt8j jx05nzc16alj8
26 Jul 22
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
1:32pm
8-K
mcug914upio
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
8-K
k60jou zjg9yju3
15 Jul 22
Departure of Directors or Certain Officers
8:28pm
424B3
ife6o2wd
6 Jul 22
Prospectus supplement
2:43pm
EFFECT
atla56ca
30 Jun 22
Notice of effectiveness
12:15am
CORRESP
4kkvq
27 Jun 22
Correspondence with SEC
12:00am